The authors concluded that ACEIs reduced all-cause mortality, cardiovascular mortality and major cardiovascular events in patients with diabetes mellitus whereas ARBs had no beneficial effects on these outcomes. These conclusions reflect the evidence presented and appear reliable.
Study selection
Eligible trials were randomised controlled trials that compared ACEIs or ARBs (any dose or type) with placebo, no treatment or other antihypertensive drugs (including ACEIs or ARBs) in people with diabetes mellitus. Trials that reported post hoc and subgroup analyses for people with diabetes mellitus were included. Trials had to report cardiovascular death or all-cause mortality outcomes with at least a 12-month mean or median follow-up.
The ACEIs studied were enalapril, captopril, perindopril, fosinopril, ramipril and lisinopril; ARBs studied were candesartan, telmisartan, losartan, irbesartan and olmesartan. Active treatment comparisons were nifedipine, nisoldipine, amlodipine, atenolol and enalapril. Most studies were of people with type 2 diabetes. In six studies none of the participants had hypertension at baseline. Mean age of participants ranged from 29 to 76 years. Follow-up ranged from 12 to 108 months.
Two reviewers independently selected trials for inclusion.
Assessment of study quality
Study quality was assessed in terms of allocation concealment, intention-to-treat analysis, blinding of investigators, participants and outcome assessors, and completeness of follow-up. The Jadad scale was also used.
Two reviewers independently assess study quality.
Data extraction
Data to calculate risk ratios with 95% confidence intervals were extracted for all-cause mortality, cardiovascular deaths and a composite measure of major cardiovascular events (cardiovascular death, non-fatal myocardial infarction, stroke, congestive heart failure and coronary artery bypass graft or percutaneous coronary intervention). Outcomes were based on the longest follow-up period available for each study.
The authors did not state how many reviewers extracted data.
Methods of synthesis
A random-effects model was used to pool risk ratios. Results were confirmed by a Mantel-Haenszel fixed-effect model. Primary analyses were done after stratifying studies based on comparator (placebo versus active treatment). Heterogeneity was assessed using the Ι² statistic. Publication bias was assessed by funnel plot and Begg test. Subgroup analyses were used to explore heterogeneity related to participants, agent used and trial quality.
